Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences total assets
Total assets on the balance sheet at the end of each period.
Emmaus Life Sciences's total assets was $16.37M at Jun 30, 2026. For fiscal 2025 it was $21.44M, down 9.2% from the year before. Over ten years it grew 32.0% a year on average. The highest annual figure on record is $59.54M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.44M | -9.2% |
| FY2024 | Dec 31, 2024 | $23.60M | -32.9% |
| FY2023 | Dec 31, 2023 | $35.18M | -27.1% |
| FY2022 | Dec 31, 2022 | $48.23M | -15.0% |
| FY2021 | Dec 31, 2021 | $56.73M | -4.7% |
| FY2020 | Dec 31, 2020 | $59.54M | +0.1% |
| FY2019 | Dec 31, 2019 | $59.46M | +875.3% |
| FY2017 | Sep 30, 2017 | $6.10M | +1090.4% |
| FY2016 | Sep 30, 2016 | $512.10K | -9.7% |
| FY2015 | Sep 30, 2015 | $567.10K | -57.6% |
| FY2014 | Sep 30, 2014 | $1.34M | -4.7% |
| FY2013 | Sep 30, 2013 | $1.40M | +1019.1% |
| FY2012 | Sep 30, 2012 | $125.30K | -66.1% |
| FY2011 | Sep 30, 2011 | $370.00K | +55.8% |
| FY2010 | Sep 30, 2010 | $237.50K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $16.37M | -29.9% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $18.70M | -20.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $21.44M | -21.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $20.76M | -20.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $23.34M | -21.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $23.60M | -32.9% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $27.34M | -42.4% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $25.94M | -48.4% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $29.54M | -39.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $35.18M | -27.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $47.45M | +12.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $50.29M | +9.3% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $48.95M | -4.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $48.23M | -15.0% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $42.20M | -29.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $45.99M | -27.3% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $51.49M | -17.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $56.73M | -4.7% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $60.06M | +0.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $63.28M | +12.5% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $62.22M | -5.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $59.54M | +0.1% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $59.94M | -4.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $56.25M | -21.0% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $65.99M | +982.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $59.46M | +4797.5% |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | $62.83M | +2485.4% |
| Q2 FY2019CQ2 2018 | Mar 31, 2019 | $71.22M | +3883.7% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $6.10M | +1090.4% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $1.21M | +71.9% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $2.43M | +268.3% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $1.79M | +93.4% |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $512.10K | -9.7% |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $706.40K | +158.7% |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $659.90K | +45.4% |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | $924.30K | +82.3% |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | $567.10K | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | $273.10K | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | $453.70K | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | $507.10K | – |
See a number that looks wrong?